RECISTResponse Evaluation Criteria in Solid Tumors (oncology review criteria)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The primary efficacy endpoint is progression-free survival (PFS) as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors (RECIST).
Secondary endpoints as determined by independent radiologic review using modified RECIST include Objective Response Rate and Overall Survival.
Opdivo and Yervoy demonstrated a disease control rate (DCR) of 54%, 43% and 49% per BICR using RECIST v1.1 across treatment arms A, B and C, respectively.
In addition, median time to progression (TTP) was doubled with LENVIMA compared to sorafenib: 7.4 months versus 3.7 months (HR: 0.60; 95% CI: 0.51-0.71; p<0.0001) per blinded independent imaging review based on mRECIST criteria, and 7.4 months with LENVIMA versus 3.7 months with sorafenib (HR: 0.61; 95% CI: 0.51-0.72; p<0.0001) per RECIST 1.1.
Response was assessed as a symptomatic improvement by ECOG grading and tumor response by RECIST 1.0 criteria.
With this background, a descriptive study was aimed to determine the correlation between the WHO response criteria and RECIST response criteria in Locally Advanced Breast Cancer following Neoadjuvant chemotherapy.
Arguably, the most widely accepted method is that of the Response Evaluation Criteria in Solid Tumors (RECIST) [1], which formalizes a set of rules for characterizing the size of nodules and changes in nodules based on one-dimensional (1D) measurements.
After four courses of chemotherapy, the response was defined as stable disease by the RECIST criteria; however, a slight enlargement of the tumor and increased enhancement effect were observed.
There are multiple, well-recognized limitations (limited discrimination and reproducibility of results, presence of "nonmeasurable disease," and inability to measure treatment benefit manifested as tumor necrosis) of the standard RECIST criteria, which rely on changes in the diameter of a few selected lesions on serial CT scans.